List of Sensipar drug patents

Sensipar is owned by Amgen.

Sensipar contains Cinacalcet Hydrochloride.

Sensipar has a total of 2 drug patents out of which 0 drug patents have expired.

Sensipar was authorised for market use on 08 March, 2004.

Sensipar is available in tablet;oral dosage forms.

Sensipar can be used as method of treating hyperparathyroidism; method of treating hypercalcemia.

The generics of Sensipar are possible to be released after 22 September, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7829595 AMGEN Rapid dissolution formulation of a calcium receptor-active compound
Sep, 2026

(3 years from now)

US9375405 AMGEN Rapid dissolution formulation of a calcium receptor-active compound
Sep, 2026

(3 years from now)

Drugs and Companies using CINACALCET HYDROCHLORIDE ingredient

Market Authorisation Date: 08 March, 2004

Treatment: Method of treating hyperparathyroidism; Method of treating hypercalcemia

Dosage: TABLET;ORAL

How can I launch a generic of SENSIPAR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic